Onyx Pharmaceuticals, Inc.

Bayer Healthcare LLC

Psioxus Therapeutics Limited

Gladiator Biosciences, Inc.

Coagulant Therapeutics Corporation

Other

Bayer Schering Pharma Ag

Bayer Intellectual Property Gmbh

Terry Hermiston

Maxine Bauzon

Irene Kuhn

Paul Harden

Sylvie Laquerre

Ye Jin

Leisa Johnson

Uwe Gritzan

Michael Strerath

Frank Dittmer

Ali Fattaey

John E Murphy

Yuqiao Shen

Julie Nye

Timothy Myles

Fang Jin

Peter Kretschmer

Christopher H Contag

John R Murphy

Richard N Harkins

Jerry Yuqiao Shen

Masamitsu Kanada

Jonathan Hardy

Lynda K Hawkins

Peter Droescher

Paul Szymanski

Konstantin Levitsky

A method of targeting extracellular vesicles employing a molecule comprising a GLA domain and extracellular vesicles obtained or obtainable from a method are described herein.

Method of targeting exosomes

Short-acting Factor VII peptides are disclosed. A shortened half-life is desirable for treatment of acute bleeding and similar disorders. Modification of the sialylation and/or glycosylation of Factor VII and variants thereof produced peptides useful in treating conditions of acute bleeding.

Short-acting Factor VII polypeptides

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis.

GLA domains as therapeutic agents

The disclosure relates to the recombinant Gla domain proteins and their use targeting phosphatidylserine (PtdS) moieties on the surface of cells, particularly those expressing elevated levels of PtdS, such as cells undergoing apoptosis. These proteins can be linked to both diagnostic and therapeutic payloads, thereby permitting identification and treatment of cells expression elevated PtdS.

Gla domains as targeting agents

Short-acting factor VII polypeptides

This patent document relates to antibodies, antigen-binding antibody fragments (Fabs), and other protein scaffolds, directed against human antithrombin &#x3b2; complexed with heparin and/or heparin-like structure (AT&#x3b2;H). These AT&#x3b2;H binding proteins can block the anti-coagulant activity of AT&#x3b2; to induce coagulation. Therapeutic uses of these antibodies and binders are described herein as are methods of panning and screening specific antibodies.

Monoclonal antibodies against antithrombin beta

Provided herein are protein biomarkers for NETosis related diseases, including proteases. Also provided are substrate sequences of such proteases and uses thereof.

Application of N-terminomics to NETosis in inflammation

Monoclonal antibodies against antithrombin &#x3b2;

The present invention relates to oncolytic adenoviruses having therapeutic applications. Recombinant chimeric adenoviruses, and methods to produce them are provided. The chimeric adenoviruses of the invention comprise nucleic acid sequences derived from adenoviral serotypes classified within the subgroups B through F and demonstrate an enhanced therapeutic index.

Chimeric adenoviruses for use in cancer treatment

The method of the invention provides for producing a heterologous protein in mammalian host cells having nucleic acid encoding Hepatitis B X protein and the heterologous protein, by growing mammalian host cells selected from the group consisting of HKB11, CHO, BHK21, C2C12, and HEK293 cells, by growing mammalian host cells in non-adherent suspension culture, or by growing mammalian host cells which contain nucleic acid providing exogenous X-box Binding Protein, XBP1s. The conditions should be such that HBx, exogenous XBP1s if present, and the heterologous protein are expressed by the mammalian cells. The invention includes compositions for carrying out the method.

Methods and compositions for production of recombinant protein in HBX-expressing mammalian cells

Growing community of inventors

Corte Madera, CA, United States of America

Terry Hermiston